Univasc and Haemoglobin decreased - a phase IV clinical study of FDA data


Haemoglobin decreased is found among people who take Univasc, especially for people who are female, 60+ old.

The phase IV clinical study analyzes which people take Univasc and have Haemoglobin decreased. It is created by eHealthMe based on reports of 967 people who have side effects when taking Univasc from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Aug, 17, 2022

967 people reported to have side effects when taking Univasc.
Among them, 9 people (0.93%) have Haemoglobin decreased.

What is Univasc?

Univasc has active ingredients of moexipril hydrochloride. It is often used in high blood pressure. eHealthMe is studying from 979 Univasc users for its effectiveness, alternative drugs and more.

What is Haemoglobin decreased?

Haemoglobin decreased is found to be associated with 2,955 drugs and 2,989 conditions by eHealthMe.

Number of Univasc and Haemoglobin decreased reports submitted per year:

Could Univasc cause Haemoglobin decreased?

Gender of people who have Haemoglobin decreased when taking Univasc *:

  • female: 66.67 %
  • male: 33.33 %

Age of people who have Haemoglobin decreased when taking Univasc *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 12.5 %
  • 60+: 87.5 %

Common drugs people take besides Univasc *:

  1. Lasix: 6 people, 66.67%
  2. Digoxin: 6 people, 66.67%
  3. Klor-Con: 5 people, 55.56%
  4. Meloxicam: 4 people, 44.44%
  5. Lisinopril: 4 people, 44.44%
  6. Nitroglycerin: 4 people, 44.44%
  7. Meclizine: 4 people, 44.44%
  8. Enalapril Maleate: 3 people, 33.33%
  9. Metoprolol Tartrate: 3 people, 33.33%
  10. Mobic: 3 people, 33.33%

Common side effects people have besides Haemoglobin decreased *:

  1. Chest Pain: 6 people, 66.67%
  2. Fluid Overload (too much fluid in the blood): 4 people, 44.44%
  3. Cardiac Failure Congestive: 4 people, 44.44%
  4. Breathing Difficulty: 4 people, 44.44%
  5. Joint Pain: 4 people, 44.44%
  6. Congestive Cardiomyopathy (weakening of heart muscle): 3 people, 33.33%
  7. Coronary Heart Disease (narrowing or blockage of the coronary arteries): 3 people, 33.33%
  8. Peripheral Vascular Disorder: 3 people, 33.33%
  9. Cardiac Valve Disease (heart valve disease): 3 people, 33.33%
  10. Multiple Injuries: 3 people, 33.33%

Common conditions people have *:

  1. Type 2 Diabetes: 2 people, 22.22%
  2. Stress And Anxiety: 1 person, 11.11%

* Approximation only. Some reports may have incomplete information.

Do you take Univasc and have Haemoglobin decreased?

Check whether Haemoglobin decreased is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Haemoglobin decreased and when was it recovered:

Expand to all the drugs that have ingredients of moexipril hydrochloride:

Alternative drugs to, pros and cons of Univasc:

Haemoglobin decreased treatments and more:

COVID vaccines that are related to Haemoglobin decreased:

Common drugs associated with Haemoglobin decreased:

All the drugs that are associated with Haemoglobin decreased:

Common conditions associated with Haemoglobin decreased:

All the conditions that are associated with Haemoglobin decreased:

How the study uses the data?

The study uses data from the FDA. It is based on moexipril hydrochloride (the active ingredients of Univasc) and Univasc (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: